search
Back to results

Marin Protein Hydrolysate and Metabolic Syndrome (MPH_MetS)

Primary Purpose

Metabolic Syndrome

Status
Completed
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
MPH_active
MPH_placebo
Sponsored by
Helse Møre og Romsdal HF
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metabolic Syndrome focused on measuring Dietary Supplements, Fish Proteins, Protein Hydrolysates

Eligibility Criteria

40 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Age 40-70 years

  • BMI 27-35 kg/m2
  • Signed informed consent
  • MetS as defined by the presence of at least 3 of the 5 following criteria*:

    • Elevated waist circumference ≥ 94 cm (M), ≥ 80 cm (F)
    • Elevated triglycerides ≥ 1.7 mmol/L (150 mg/dL)
    • Elevated fasting glucose ≥ 5.5 mmol/L (100 mg/dL)
    • Elevated blood pressure S ≥ 130 and/or D ≥85 mmHg
    • Reduced HDL-cholesterol < 1.0 mmol/L (40 mg/dL) (M) <1.3 mmol/L (50 mg/dL) (F)

      • The International Diabetes Foundations (IDF) cut-off points are used.

Exclusion Criteria:

  • Suspected allergy against fish or shellfish
  • Acute infections (may be reconsidered for inclusion at a later time)
  • Chronic disease or therapies that is likely to interfere with the evaluation study results
  • Pregnancy, lactation or planning pregnancy during study period
  • Substance misuse
  • Inability or unwillingness to comply with the requirements of study procedures

Sites / Locations

  • Haukeland University Hospital
  • Ålesund Hospital, Helse Møre og Romsdal HF

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

MPH_active

MPH_placebo

Arm Description

Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.

Daily intake at breakfast of supplementary placebo. Random sequence of arms.

Outcomes

Primary Outcome Measures

Glucose
Postprandial glucose (mmol/L) change at baseline and after 8 weeks on intervention.

Secondary Outcome Measures

Insulin
Postprandial insulin (mmol/L) change at baseline and after 8 weeks on intervention.
Hormon hunger 1
Glucagon like peptide 1 (GLP-1) pmol/l at baseline and after 8 weeks on intervention.
Hormon hunger 2
Ghrelin at baseline and after 8 weeks on intervention.
Body composition 1
Bioimpedance at baseline and after 8 weeks on intervention.
Body composition 2
Body mass index at baseline and after 8 weeks on intervention.
Body composition 3
Waist circumference at baseline and after 8 weeks on intervention.
Glucose_met
Glycated hemoglobin (HBA1c) at baseline and after 8 weeks on intervention.

Full Information

First Posted
January 15, 2019
Last Updated
December 21, 2020
Sponsor
Helse Møre og Romsdal HF
Collaborators
Haukeland University Hospital, University of Bergen
search

1. Study Identification

Unique Protocol Identification Number
NCT03807752
Brief Title
Marin Protein Hydrolysate and Metabolic Syndrome
Acronym
MPH_MetS
Official Title
The Effect of Supplementation With a Marine Protein Hydrolysate in Patients With Metabolic Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Completed
Study Start Date
February 15, 2019 (Actual)
Primary Completion Date
December 31, 2019 (Actual)
Study Completion Date
April 30, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Helse Møre og Romsdal HF
Collaborators
Haukeland University Hospital, University of Bergen

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Overweight and obesity are increasing global health problems and the most important contributors to morbidity and mortality. The maintenance of long-term weight loss is difficult, and individuals often regain weight after an intervention program is finished. It is of interest to find ways to prevent and alleviate metabolic syndrome (MetS), beyond the known effects of lifestyle modification and weight loss. Fish has been proposed as a food that may have favorable effects on metabolic health. There is evidence that cod, and other marine fish, may contain bioactive peptides that have potentially important health effects in humans. The aim of this study is to investigate the effect of adding a marine protein hydrolysate (MPH) supplement to the diet over an 8-week period in a group of adults with established MetS. The investigators expect that this will lead to beneficial changes in the components of MetS and to an overall healthier metabolic profile.
Detailed Description
Overweight and obesity are increasing global health problems and the most important contributors to morbidity and mortality. Obesity (abdominal obesity), together with hyperglycemia, dyslipidemia and hypertension forms a cluster of risk factors that is called the metabolic syndrome (MetS). The first-line therapy for MetS is lifestyle intervention - education on a healthy lifestyle leading to a focus on physical activity and diet, which will improve risk factors closely linked to MetS. The maintenance of long-term weight loss is difficult, and individuals often regain weight after an intervention program stops. It is of interest to find ways to prevent and alleviate MetS, beyond the known effects of lifestyle modification and weight loss. Fish has been proposed as a food that may have favorable effects on metabolic health. Previous intervention studies with fish protein in humans and rodents have shown improved insulin sensitivity and glucose tolerance, reduced cholesterol levels in plasma and reduced blood pressure. Intervention studies investigating the effect of cod have mainly focused on the health effect of consuming the whole fillet. Studies on the remaining part of the fish, the residual material, primarily used for production of animal feed, are scarce. There is evidence that cod, and other marine fish, may contain bioactive peptides that have potentially important health effects in humans. Therefore, it is of interest to investigate the possible effect of a daily supplement of marine protein hydrolysate (MPH), taken over a longer period, in a group of patients with abnormal glucose control. The aim of this study is to investigate the effect of adding a MPH supplement to the diet over an 8-week period in a group of adults with established MetS. The investigators expect that supplementation with MPH will lead to beneficial changes in the components of MetS and an overall healthier metabolic profile.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome
Keywords
Dietary Supplements, Fish Proteins, Protein Hydrolysates

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A parallel group randomized, controlled clinical trial for eight weeks
Masking
ParticipantCare ProviderInvestigator
Masking Description
The provider of the dietary supplement deliver the supplement prepared and packed in equal bags (active/placebo) that we hand out to the participants in an randomized order.
Allocation
Randomized
Enrollment
33 (Actual)

8. Arms, Groups, and Interventions

Arm Title
MPH_active
Arm Type
Active Comparator
Arm Description
Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
Arm Title
MPH_placebo
Arm Type
Placebo Comparator
Arm Description
Daily intake at breakfast of supplementary placebo. Random sequence of arms.
Intervention Type
Dietary Supplement
Intervention Name(s)
MPH_active
Intervention Description
One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
Intervention Type
Dietary Supplement
Intervention Name(s)
MPH_placebo
Intervention Description
One daily intake at breakfast of supplementary placebo, a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
Primary Outcome Measure Information:
Title
Glucose
Description
Postprandial glucose (mmol/L) change at baseline and after 8 weeks on intervention.
Time Frame
At baseline and after 8 weeks, the first sample fasted, thereafter repeated samples every 20 minutes (i.e. -15, 0, 20, 40, 60, 80, 100,120 minutes after baseline).
Secondary Outcome Measure Information:
Title
Insulin
Description
Postprandial insulin (mmol/L) change at baseline and after 8 weeks on intervention.
Time Frame
At baseline and after 8 weeks, the first sample fasted, thereafter repeated samples every 20 minutes (i.e. -15, 0, 20, 40, 60, 80, 100,120 minutes after baseline).
Title
Hormon hunger 1
Description
Glucagon like peptide 1 (GLP-1) pmol/l at baseline and after 8 weeks on intervention.
Time Frame
At baseline and after 8 weeks, the first sample fasted, thereafter repeated samples (i.e - 15, 0, 20, 40, 80, 120 minutes after baseline).
Title
Hormon hunger 2
Description
Ghrelin at baseline and after 8 weeks on intervention.
Time Frame
At baseline and after 8 weeks, the first sample fasted, thereafter repeated samples (i.e - 15, 0, 20, 40, 80, 120 minutes after baseline).
Title
Body composition 1
Description
Bioimpedance at baseline and after 8 weeks on intervention.
Time Frame
At baseline and after 8 weeks.
Title
Body composition 2
Description
Body mass index at baseline and after 8 weeks on intervention.
Time Frame
At baseline and after 8 weeks.
Title
Body composition 3
Description
Waist circumference at baseline and after 8 weeks on intervention.
Time Frame
First at baseline and after 8 weeks.
Title
Glucose_met
Description
Glycated hemoglobin (HBA1c) at baseline and after 8 weeks on intervention.
Time Frame
At baseline and after 8 weeks.
Other Pre-specified Outcome Measures:
Title
Inflammation
Description
High-sensitive C-reactive protein at baseline and after 8 weeks on intervention.
Time Frame
At baseline and after 8 weeks.
Title
Hormon 2
Description
Adiponectin at baseline and after 8 weeks on intervention.
Time Frame
Fasted at baseline and after 8 weeks.
Title
Hormon 1
Description
Leptin at baseline and after 8 weeks on intervention.
Time Frame
Fasted at baseline and after 8 weeks.
Title
Lipid profile 1
Description
Triglycerides at baseline and after 8 weeks on intervention.
Time Frame
Fasted at baseline and after 8 weeks.
Title
Lipid profile 2
Description
Total cholesterol at baseline and after 8 weeks on intervention.
Time Frame
Fasted at baseline and after 8 weeks.
Title
Lipid profile 3
Description
HDL-cholesterol at baseline and after 8 weeks on intervention.
Time Frame
Fasted at baseline and after 8 weeks.
Title
Lipid profile 4
Description
LDL-cholesterol at baseline and after 8 weeks on intervention.
Time Frame
Fasted at baseline and after 8 weeks.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 40-70 years BMI 27-35 kg/m2 Signed informed consent MetS as defined by the presence of at least 3 of the 5 following criteria*: Elevated waist circumference ≥ 94 cm (M), ≥ 80 cm (F) Elevated triglycerides ≥ 1.7 mmol/L (150 mg/dL) Elevated fasting glucose ≥ 5.5 mmol/L (100 mg/dL) Elevated blood pressure S ≥ 130 and/or D ≥85 mmHg Reduced HDL-cholesterol < 1.0 mmol/L (40 mg/dL) (M) <1.3 mmol/L (50 mg/dL) (F) The International Diabetes Foundations (IDF) cut-off points are used. Exclusion Criteria: Suspected allergy against fish or shellfish Acute infections (may be reconsidered for inclusion at a later time) Chronic disease or therapies that is likely to interfere with the evaluation study results Pregnancy, lactation or planning pregnancy during study period Substance misuse Inability or unwillingness to comply with the requirements of study procedures
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dag Arne Lihaug Hoff, MD, PhD
Organizational Affiliation
Helse Møre og Romsdal Hospital Trust
Official's Role
Study Director
Facility Information:
Facility Name
Haukeland University Hospital
City
Bergen
Country
Norway
Facility Name
Ålesund Hospital, Helse Møre og Romsdal HF
City
Ålesund
Country
Norway

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33171589
Citation
Jensen C, Dale HF, Hausken T, Hatlebakk JG, Bronstad I, Lied GA, Hoff DAL. The Effect of Supplementation with Low Doses of a Cod Protein Hydrolysate on Satiety Hormones and Inflammatory Biomarkers in Adults with Metabolic Syndrome: A Randomized, Double-Blind Study. Nutrients. 2020 Nov 8;12(11):3421. doi: 10.3390/nu12113421.
Results Reference
background
PubMed Identifier
32635503
Citation
Jensen C, Fjeldheim Dale H, Hausken T, Hatlebakk JG, Bronstad I, Lied GA, Hoff DAL. Supplementation with Low Doses of a Cod Protein Hydrolysate on Glucose Regulation and Lipid Metabolism in Adults with Metabolic Syndrome: A Randomized, Double-Blind Study. Nutrients. 2020 Jul 4;12(7):1991. doi: 10.3390/nu12071991.
Results Reference
result

Learn more about this trial

Marin Protein Hydrolysate and Metabolic Syndrome

We'll reach out to this number within 24 hrs